Maplight Therapeutics (NASDAQ:MPLT – Get Free Report) was upgraded by equities research analysts at Lifesci Capital to a “strong-buy” rating in a report released on Thursday,Zacks.com reports.
Other equities research analysts have also issued reports about the stock. Wall Street Zen lowered shares of Maplight Therapeutics from a “hold” rating to a “sell” rating in a research note on Saturday, March 21st. Needham & Company LLC started coverage on shares of Maplight Therapeutics in a research note on Wednesday, April 8th. They set a “buy” rating and a $37.00 target price for the company. Canaccord Genuity Group started coverage on shares of Maplight Therapeutics in a research note on Thursday, March 19th. They set a “buy” rating and a $35.00 target price for the company. HC Wainwright started coverage on shares of Maplight Therapeutics in a research note on Monday, May 4th. They set a “buy” rating and a $45.00 target price for the company. Finally, TD Cowen started coverage on shares of Maplight Therapeutics in a research note on Tuesday, April 7th. They set a “buy” rating for the company. Two analysts have rated the stock with a Strong Buy rating, seven have given a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat, Maplight Therapeutics has an average rating of “Moderate Buy” and an average price target of $34.43.
View Our Latest Research Report on MPLT
Maplight Therapeutics Stock Performance
Maplight Therapeutics (NASDAQ:MPLT – Get Free Report) last released its quarterly earnings data on Thursday, May 14th. The company reported ($1.34) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.91) by ($0.43). As a group, sell-side analysts forecast that Maplight Therapeutics will post -3.96 EPS for the current fiscal year.
Insider Buying and Selling
In other news, insider Erin Pennock Foff sold 4,438 shares of the company’s stock in a transaction on Thursday, May 7th. The stock was sold at an average price of $28.54, for a total value of $126,660.52. Following the completion of the sale, the insider directly owned 346,059 shares in the company, valued at $9,876,523.86. This represents a 1.27% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CEO Christopher A. Kroeger sold 13,980 shares of Maplight Therapeutics stock in a transaction on Monday, May 11th. The shares were sold at an average price of $30.11, for a total transaction of $420,937.80. Following the transaction, the chief executive officer owned 1,512,329 shares in the company, valued at approximately $45,536,226.19. This trade represents a 0.92% decrease in their position. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last quarter, insiders have bought 25,000 shares of company stock valued at $441,168 and have sold 391,204 shares valued at $11,125,068. Corporate insiders own 3.80% of the company’s stock.
Institutional Investors Weigh In On Maplight Therapeutics
A number of institutional investors have recently bought and sold shares of MPLT. Strs Ohio purchased a new stake in Maplight Therapeutics in the 4th quarter worth $53,000. Blue Owl Capital Holdings LP purchased a new stake in Maplight Therapeutics in the 4th quarter worth $5,745,000. Geode Capital Management LLC purchased a new stake in Maplight Therapeutics in the 4th quarter worth $6,835,000. Seven Grand Managers LLC purchased a new stake in Maplight Therapeutics in the 4th quarter worth $1,756,000. Finally, Goldman Sachs Group Inc. purchased a new stake in Maplight Therapeutics in the 4th quarter worth $34,026,000.
Maplight Therapeutics Company Profile
We are a clinical-stage biopharmaceutical company focused on improving the lives of patients suffering from debilitating central nervous system, or CNS, disorders. We were founded by globally recognized leaders in psychiatry and neuroscience research to address the lack of circuit-specific pharmacotherapies available for patients. Our discovery platform holds the potential to fill this void by identifying neural circuits causally linked to disease and targeting those circuits for therapeutic modulation.
Featured Stories
- Five stocks we like better than Maplight Therapeutics
- Be Ready: 3 Upcoming Catalysts Could Drive Oracle to Record Highs
- 2 Ways to Play the Big Pharma Patent Cliff
- YETI Rallies After Earnings Beat and Raised Outlook
- How the 3 Leading Quantum Firms Stack Up After Q1 Earnings
Receive News & Ratings for Maplight Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Maplight Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
